Funder: National Institutes of Health
Due Dates: February 11, 2027 (Application deadline)
Funding Amounts: $19,000,000 estimated total program funding for 6 expected cooperative agreement awards
Summary: Supports continuation of NCI clinical trials biospecimen banks that collect, process, store, and distribute clinically annotated human biospecimens for translational cancer research.
Key Information: Limited to existing NCTN biobank recipients funded under RFA-CA-20-002 or EET Biobank recipients funded under RFA-CA-20-003.
Description
The National Cancer Institute (NCI) supports continuation of two national biospecimen banking resources through this limited competition: the National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). These resources collect, process, store, and distribute high-quality, clinically annotated human biospecimens from NCI-funded treatment, prevention, and cancer control trials to enable translational cancer research.
NCTN Biobanks support NCTN and the Community Oncology Research Program (NCORP), enabling biomarker development and validation, secondary correlative studies, and discovery using harmonized specimens linked to clinical outcomes. The EET Biobank supports the Experimental Therapeutics Clinical Trials Network (ETCTN) and other NCI-supported early-phase and experimental trials involving investigational agents. Its specimens support biomarker assays, pharmacokinetic and pharmacodynamic analyses, studies of drug response and resistance, patient stratification, and development of novel cancer therapies.
